InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

Rhea-AI Summary

InMed (NASDAQ: INM) reported third quarter fiscal 2026 results for the period ended March 31, 2026. The company highlighted new preclinical INM-901 data in human 3D brain organoids showing dose-dependent reductions in IL-6 and IL-8 and alignment with prior in vivo/ex vivo results. The board approved winding down BayMedica commercial operations; discontinued operations generated $0.7M during the quarter. Continuing operations reported a quarterly net loss of $3.0M, R&D of $1.0M, and cash, cash equivalents and short-term investments of $5.2M as of March 31, 2026.

Positive

• INM-901 showed dose-dependent reduction of IL-6 and IL-8 in human 3D brain organoids
• Anti-neuroinflammatory effects were consistent across in vivo, ex vivo, and human organoid systems
• Discontinued segment generated $0.7M in revenue during the quarter

Negative

• Cash and short-term investments declined to $5.2M from $10.8M on June 30, 2025
• Net loss widened to $3.0M for the quarter versus $2.1M year-ago quarter
• Board approved wind-down of BayMedica commercial operations, reducing ongoing revenue sources
• Research and development expense for continuing operations rose to $1.0M from $0.4M

News Market Reaction – INM

-4.13%

1 alert

-4.13% Session close to close

$2.55M Market Cap

0.6x Rel. Volume

In the May 7 session, INM declined 4.13%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement combines Q3 FY2026 financials with an update on INM-901’s anti-neuroinflammatory d...

Analysis

This announcement combines Q3 FY2026 financials with an update on INM-901’s anti-neuroinflammatory data in human brain organoids. It shows a wider net loss of $3.0M, higher R&D of $1.0M, and a cash balance of $5.2M while BayMedica’s commercial unit is treated as discontinued operations. Investors may track future quarters for cash usage, any draws under the $50,000,000 shelf and ATM, and milestones toward planned INM-901 and INM-089 IND filings.

Key Figures

Net loss (Q3 2026): $3.0M Net loss (Q3 2025): $2.1M R&D expense: $1.0M +5 more

8 metrics

Net loss (Q3 2026) $3.0M Three months ended March 31, 2026; continuing and discontinued combined

Net loss (Q3 2025) $2.1M Three months ended March 31, 2025; prior-year comparison

R&D expense $1.0M Continuing operations, three months ended March 31, 2026

R&D expense prior year $0.4M Continuing operations, three months ended March 31, 2025

G&A expense $1.7M Continuing operations, three months ended March 31, 2026

Cash & equivalents $5.2M As of March 31, 2026, including short-term investments

Cash & equivalents prior $10.8M As of June 30, 2025, including short-term investments

Revenue (discontinued ops) $0.7M BayMedica commercial operations during the quarter, classified as discontinued

Previous Earnings Reports

5 past events · Latest: Feb 11 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 11	Q2 FY2026 earnings	Negative	-10.1%	Q2 FY2026 loss, lower BayMedica revenue, and highlighted legislative risk.
Nov 06	Q1 FY2026 earnings	Negative	-6.2%	Q1 FY2026 loss with declining BayMedica revenue and lower cash balance.
Sep 23	FY2025 results	Positive	-5.7%	FY2025 revenue growth, adequate cash runway, and pipeline progress updates.
May 12	Q3 FY2025 earnings	Positive	+14.9%	Q3 FY2025 results with BayMedica revenue growth and pipeline advancement.
Feb 12	Q2 FY2025 earnings	Negative	-3.1%	Q2 FY2025 loss, lower commercial revenue, and higher operating expenses.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Earnings and financial updates have usually been followed by negative single-day moves, with only one notable positive reaction in the past five such reports.

Recent Company History

Over the last year, InMed’s earnings and financial updates have generally coincided with share price weakness. Prior events on Feb 11, 2026 and Nov 6, 2025 highlighted ongoing net losses, declining BayMedica revenue, and legislative risk, with 24-hour moves from -6.16% to -10.09%. A full-year report on Sep 23, 2025 showed revenue growth and sufficient cash into Q4 2026 yet still saw a -5.73% reaction, while only Q3 FY2025 on May 12, 2025 produced a strong +14.91% response.

Key Terms

neuroinflammation, 3d human brain organoid models, lipopolysaccharide ("lps"), interferon-gamma ("ifn-γ"), +4 more

8 terms

neuroinflammation medical

"INM-901 for Alzheimer's disease through its targeting of neuroinflammation."

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

3d human brain organoid models medical

"preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models"

Three-dimensional human brain organoid models are small, lab-grown clusters of human brain cells that self-organize into tissue-like structures, serving as simplified, scaled-down replicas of certain aspects of the brain. They matter to investors because they allow companies to test drugs, study diseases and screen safety earlier and more cheaply than full clinical trials, offering earlier signals about whether a therapy is likely to work or fail — like a prototype that helps de-risk product development.

lipopolysaccharide ("lps") medical

"neuroinflammation induced with lipopolysaccharide ("LPS") and interferon-gamma"

A lipopolysaccharide (LPS) is a large molecule found on the outer surface of certain bacteria that acts like a powerful alarm bell to the immune system, often triggering inflammation or fever. Investors should care because LPS is a target for drugs, a source of dangerous contamination in biologic manufacturing and medical devices, and a factor that can influence clinical trial safety, regulatory reviews, and the commercial viability of therapies and diagnostics.

interferon-gamma ("ifn-γ") medical

"induced with lipopolysaccharide ("LPS") and interferon-gamma ("IFN-γ")"

Interferon-gamma (IFN-γ) is a naturally produced immune signaling protein that tells immune cells to activate and coordinate attacks against infections and abnormal cells; think of it as a smoke alarm that raises the alert level across the immune system. Investors care because IFN-γ itself or drugs that change its levels can be the focus of therapies, clinical trial outcomes, safety issues, biomarkers, and regulatory decisions—factors that materially affect a biotech company's prospects and valuation.

il-6 medical

"dose-dependent reduction of key pro-inflammatory markers such as IL-6 and IL-8"

Interleukin-6 (IL-6) is a small signaling protein the body releases as an alarm during infection, injury, or chronic inflammation; think of it as a smoke detector that calls immune cells to action. It matters to investors because IL-6 levels can serve as a biomarker for disease severity and a target for therapies—drugs that block or modulate IL-6 can change treatment outcomes, regulatory decisions, and commercial prospects in healthcare markets.

il-8 medical

"dose-dependent reduction of key pro-inflammatory markers such as IL-6 and IL-8"

IL-8 is a small signaling protein produced by cells that acts like a distress signal calling immune cells to sites of inflammation or infection. Investors care because IL-8 levels can serve as a biomarker of disease activity and treatment response, and therapies that change IL-8 signaling may become drug targets or affect clinical trial outcomes, influencing a biotech company's valuation and market potential.

discontinued operations financial

"classified the Commercial segment as discontinued operations, the Company has one reportable segment"

Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.

right-of-use asset financial

"Recognition of Right-of-use asset and corresponding operating lease"

A right-of-use asset is the value a company records on its balance sheet for the practical use of something it leases — like the benefit of living in a rented office or using leased equipment for a set period. Investors care because it turns many leases into on-balance-sheet assets and matching liabilities, which can change reported leverage, asset base and performance metrics much like taking on a loan would.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026 which ended March 31, 2026.

The Company's full financial statements and related MD&A for the third quarter ended March 31, 2026, are available at www.inmedpharma.com, www.sedarplus.com and at www.sec.gov.

"During the quarter, InMed reported additional preclinical data that further support the development of INM-901 for Alzheimer's disease through its targeting of neuroinflammation. Data from advanced human brain organoid systems demonstrated anti-neuroinflammatory effects consistent with findings observed across multiple in vivo and ex vivo studies," commented Eric A. Adams, InMed President and CEO.

Business Update

INM-901: Targeting the Modulation of Neuroinflammation in Alzheimer's disease
InMed's proprietary, disease-modifying, small molecule drug candidate INM-901 is a preferential signaling agonist of the CB1/CB2 receptors and continues to advance as a potential treatment for Alzheimer's disease with a primary focus on modulating neuroinflammation. During the quarter, InMed announced preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer's disease.

The in vitro human organoid models represent some of the closest approximations to human brain tissue currently available, incorporating a complex cellular environment relevant to neurodegenerative disease. The organoids are composed of neurons, astrocytes, vascular cells and feature microglia, the brain's resident immune cells, and can be used to bridge the gap between traditional animal models and human clinical trials.

INM-901 was evaluated in two distinct human 3D organoid models: a general model of neuroinflammation induced with lipopolysaccharide ("LPS") and interferon-gamma ("IFN-γ"); and, Stem Pharm's proprietary neuroinflammation Alzheimer's disease model with specific features observed in Alzheimer's disease patients.

Key Observations included:

• INM-901 demonstrated significant reduction in neuroinflammation in Stem Pharm's LPS-induced model and in their Alzheimer's disease model. A dose-dependent reduction of key pro-inflammatory markers such as IL-6 and IL-8 was seen in both neuroinflammation models.

• Effects align with prior findings from an in vivo Alzheimer's model and an ex vivo LPS-induced neuroinflammation model.

• Provides supportive evidence of mechanistic translation from animal models to human tissue systems.

The consistency of INM-901's anti-inflammatory effects across in vivo animal models, ex vivo systems and now human 3D brain organoids provide increasing confidence in the compound's potential to translate into clinical benefit in humans with neuroinflammatory conditions.

Discontinued Operations
On March 4, 2026, the Company's board of directors ratified, confirmed and approved the decision of the board members of BayMedica to wind down and exit BayMedica's commercial operations business segment ("Commercial Operations"), which is the only revenue-generating commercial operations of the Company. BayMedica intends to substantially complete the wind down and exit prior to the end of its fiscal year ending June 30, 2026. During the interim period leading to the completion of operational wind down, BayMedica will continue its commercial operations including sales, marketing, limited manufacturing, and logistics.

Financial Commentary

Following the classification of the Commercial segment as discontinued operations, the Company has one reportable segment that constitutes consolidated results consisting of its operations. Unless otherwise noted, all activities and amounts reported in the following notes relate to the continuing operations of the Company and exclude activities and amounts related to discontinued operations.

For the three months ended March 31, 2026, the Company reported a net loss of $3.0 million, compared to a net loss of $2.1 million in the same period the previous year. The increase was largely driven by higher expenses related to pharmaceutical research and development activities, as well as financing costs.

Pharmaceutical research and development for continuing operations were $1.0 million for the three months ended March 31, 2026, compared with $0.4 million for the three months ended March 31, 2025. The increase was primarily due to an increase in external contractors relating to our INM-901 program

General and administrative expenses for continuing operations were $1.7 million for the three months ended March 31, 2026, compared to $1.6 million the same period the previous year. The increase resulted primarily from a combination of changes including lower accounting fees, share-based payments fees, and shareholder communication fees.

As of March 31, 2026, the Company's cash, cash equivalents and short-term investments were $5.2 million, which compares to $10.8 million on June 30, 2025.

The Company reported no revenue from continuing operations for the period. The discontinued commercial operations generated revenue of $0.7 million during the period; however, its results are classified as discontinued operations and are presented separately from continuing operations.

Table 1. Consolidated Balance Sheet
Expressed in U.S. Dollars

	March 31,				June 30,
	2026				2025
	Unaudited				(As restated)
	$				$
ASSETS
Current
Cash and cash equivalents		5,158,932				10,743,430
Short-term investments		41,625				43,384
Prepaids and other current assets		617,211				319,547
Current assets of discontinued operations		1,070,313				1,760,918
Total current assets		6,888,081				12,867,279
Non-Current
Property, equipment and ROU assets, net		642,884				992,199
Intangible assets, net		1,498,473				1,620,562
Other assets		104,368				100,000
Total Assets		9,133,806				15,580,040
LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities		1,011,551				1,230,845
Current portion of lease obligations		389,381				435,507
Current liabilities of discontinued operations		810,334				173,438
Total current liabilities		2,211,266				1,839,790
Non-current
Lease obligations, net of current portion		30,766				305,755
Total Liabilities		2,242,032				2,145,545
Commitments and Contingencies (Note 9)
Shareholders' Equity
Common shares, no par value, unlimited authorized shares: 3,314,063 and 2,002,186 as of March 31, 2026 and June 30, 2025, respectively, issued and outstanding		92,578,071				91,221,174
Additional paid-in capital		38,144,484				39,322,644
Accumulated deficit		(123,959,350	)			(117,237,892	)
Accumulated other comprehensive income		128,569				128,569
Total Shareholders' Equity		6,891,774				13,434,495
Total Liabilities and Shareholders' Equity		9,133,806				15,580,040

 

Table 2. Consolidated Statements of Operations
Expressed in U.S. Dollars

	For the Three Months Ended								For the Nine Months Ended
	March 31,								March 31,
	2026				2025				2026				2025
	$				$				$				$
Operating Expenses
Research and development		1,022,630				425,370				2,222,732				2,243,948
General and administrative		1,742,016				1,584,393				4,304,323				4,155,493
Amortization and depreciation		51,707				51,706				156,912				158,289
Foreign exchange loss		23,168				22,165				62,026				50,608
Total operating expenses		2,839,521				2,083,634				6,745,993				6,608,338
Other Income (Expense)
Interest and other income		47,770				16,565				215,914				104,195
Finance expense		-				-				-				(351,549	)
Net loss from continuing operations before taxes		(2,791,751	)			(2,067,069	)			(6,530,079	)			(6,855,692	)
Income tax expense		-				-				-				-
Net loss from continuing operations		(2,791,751	)			(2,067,069	)			(6,530,079	)			(6,855,692	)
Discontinued operations:
Income (Loss) from discontinued operations		(174,585	)			(53,861	)			(191,379	)			481,870
Income tax benefit		-				-				-				-
Loss from discontinued operations		(174,585	)			(53,861	)			(191,379	)			481,870
Net Loss		(2,966,336	)			(2,120,930	)			(6,721,458	)			(6,373,822	)
Net loss per share for the period
Basic and diluted:
Continuing operations		(0.69	)			(1.89	)			(1.64	)			(8.53	)
Discontinued Operations		(0.04	)			(0.05	)			(0.05	)			0.6
Net loss per share attributable to Common Stockholders – basic and diluted		(0.73	)			(1.94	)			(1.69	)			(7.93	)
Weighted average outstanding common shares
Basic and diluted		4,048,209				1,095,973				3,985,313				803,909

 

Table 3. Consolidated Statements of Cash Flows
Expressed in U.S. Dollars

	For the Nine Months Ended March 31,
	2026				2025
	$				$
Cash provided by (used in):
Operating Activities
Net loss		(6,721,458	)			(6,373,822	)
Items not requiring cash:
Amortization and depreciation		156,912				160,087
Share-based compensation		84,240				92,577
Amortization of right-of-use assets		291,245				243,555
Unrealized foreign exchange loss		27,730				44,876
Changes in operating assets and liabilities:
Prepaids and other currents assets		(294,825	)			(61,581	)
Other non-current assets		(4,368	)			-
Accounts payable and accrued liabilities		(218,577	)			(349,399	)
Lease obligations		(327,395	)			(315,221	)
Operating cash flow used by discontinued operations		1,327,501				570,483
Total cash used in operating activities		(5,678,995	)			(5,988,445	)
Investing Activities
Sale of short-term investments		41,667				40,039
Purchase of short-term investments		(41,667	)			(40,039	)
Total cash used in investing activities		-				-
Financing Activities
Proceeds from the private placement		231,675				4,361,220
Share issuance costs		(137,178	)			(264,559	)
Total cash provided by financing activities		94,497				4,096,661
Decrease in cash and cash equivalents during the period		(5,584,498	)			(1,891,784	)
Cash and cash equivalents beginning of the period		10,743,430				6,571,610
Cash and cash equivalents end of the period		5,158,932				4,679,826
SUPPLEMENTARY CASH FLOW INFORMATION:
Cash paid during the period for:		-				-
Income taxes	$	-			$	-
Interest	$	-			$	-
SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Recognition of Right-of-use asset and corresponding operating lease	$	-			$	187,223

 

About InMed

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about; the potential efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901; preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer's disease. demonstrated significant reduction in neuroinflammation in Stem Pharm's LPS-induced model and in their Alzheimer's disease model.

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, InMed's Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296317

FAQ

What did InMed (INM) report for Q3 fiscal 2026 net loss and cash balance?

InMed reported a Q3 fiscal 2026 net loss of $3.0M and cash plus short-term investments of $5.2M. According to the company, the cash decline reflects operating cash use and financing activity year-to-date.

What preclinical results did InMed announce for INM-901 on May 6, 2026?

INM-901 produced dose-dependent reductions in pro-inflammatory markers IL-6 and IL-8 in two human 3D brain organoid models. According to the company, effects aligned with prior in vivo and ex vivo neuroinflammation studies.

What does the BayMedica wind-down mean for InMed shareholders and revenue?

The board approved winding down BayMedica's commercial operations, which generated $0.7M this quarter. According to the company, the exit is expected to substantially complete by June 30, 2026, reducing ongoing revenue sources.

How did InMed's R&D and operating expenses change in Q3 fiscal 2026?

Research and development for continuing operations rose to $1.0M versus $0.4M a year earlier, driven by external contractors for INM-901. According to the company, total operating expenses were higher mainly due to R&D and financing costs.

Are InMed's INM-901 organoid data indicative of clinical translation for Alzheimer's?

The organoid results provide supportive mechanistic evidence but are preclinical and not proof of clinical benefit in humans. According to the company, consistency across animal, ex vivo, and human organoid systems increases confidence in translational potential.